Last updated on October 2018

A Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Brief description of study

The Primary Objectives of FX2016-11 and FX2016-12 are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.

Detailed Study Description

This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate the safety and efficacy of FMX103 topical foam containing 1.5% minocycline compared to vehicle, in the treatment of subjects with moderate-to-severe facial papulopustular rosacea. Qualified subjects will be randomized to receive 1 of the following 2 treatments:

  • FMX103 minocycline foam 1.5%
  • Vehicle foam

Clinical Study Identifier: NCT03142451

Contact Investigators or Research Sites near you

Start Over

Premier Research

Foamix Investigational Site # 140
Warren, MI United States